HC Wainwright Brokers Decrease Earnings Estimates for NRXP

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) – Stock analysts at HC Wainwright lowered their Q3 2026 earnings per share (EPS) estimates for NRx Pharmaceuticals in a research note issued to investors on Tuesday, August 25th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings per share of ($0.43) for the quarter, down from their prior estimate of ($0.06). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for NRx Pharmaceuticals’ current full-year earnings is ($0.30) per share. HC Wainwright also issued estimates for NRx Pharmaceuticals’ Q4 2026 earnings at ($0.50) EPS, Q1 2027 earnings at ($0.30) EPS, Q2 2027 earnings at ($0.15) EPS, Q3 2027 earnings at ($0.05) EPS, Q4 2027 earnings at $0.00 EPS, FY2027 earnings at ($0.50) EPS, FY2028 earnings at $0.15 EPS, FY2029 earnings at $0.71 EPS and FY2030 earnings at $1.14 EPS.

A number of other analysts also recently issued reports on the stock. BTIG Research restated a “buy” rating and set a $10.00 price objective on shares of NRx Pharmaceuticals in a report on Tuesday, August 18th. D. Boral Capital reiterated a “buy” rating and issued a $34.00 target price on shares of NRx Pharmaceuticals in a research note on Tuesday, May 5th. Wall Street Zen downgraded shares of NRx Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. UBS Group restated a “buy” rating on shares of NRx Pharmaceuticals in a research note on Wednesday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NRx Pharmaceuticals in a report on Wednesday, August 5th. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $34.50.

NRx Pharmaceuticals Price Performance

NASDAQ NRXP opened at $3.46 on Thursday. The business’s fifty day moving average is $3.72 and its 200-day moving average is $3.04. The stock has a market capitalization of $149.82 million, a price-to-earnings ratio of -6.29 and a beta of 2.18. NRx Pharmaceuticals has a one year low of $1.62 and a one year high of $5.05.

NRx Pharmaceuticals (NASDAQ:NRXP) last announced its quarterly earnings data on Monday, August 17th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.33). The business had revenue of $1.10 million during the quarter, compared to analysts’ expectations of $1.33 million.

Institutional Investors Weigh In On NRx Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in NRXP. Geode Capital Management LLC boosted its position in NRx Pharmaceuticals by 27.9% during the second quarter. Geode Capital Management LLC now owns 172,255 shares of the company’s stock worth $562,000 after purchasing an additional 37,598 shares during the period. Vanguard Group Inc. lifted its stake in shares of NRx Pharmaceuticals by 18.3% during the 3rd quarter. Vanguard Group Inc. now owns 534,956 shares of the company’s stock valued at $1,765,000 after buying an additional 82,781 shares in the last quarter. Two Sigma Investments LP lifted its stake in shares of NRx Pharmaceuticals by 66.4% during the 3rd quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock valued at $173,000 after buying an additional 20,880 shares in the last quarter. Global Retirement Partners LLC bought a new position in NRx Pharmaceuticals in the 4th quarter worth approximately $107,000. Finally, Bleakley Financial Group LLC bought a new position in NRx Pharmaceuticals in the 4th quarter worth approximately $318,000. 4.27% of the stock is owned by hedge funds and other institutional investors.

NRx Pharmaceuticals News Summary

Here are the key news stories impacting NRx Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright reaffirmed its Buy rating on NRx Pharmaceuticals, signaling that the analyst continues to see potential upside despite the lowered earnings forecasts. HC Wainwright Reiterates Buy Rating for NRx Pharmaceuticals
• Neutral Sentiment: Reported short-interest data showed zero shares sold short on both August 10 and August 25, with a zero-day days-to-cover ratio. Because the figures appear inconsistent and include a “NaN” change, they provide little meaningful signal for investors.
• Negative Sentiment: HC Wainwright lowered its estimated losses for NRx’s third and fourth quarters of 2026 to $0.43 and $0.50 per share, respectively, from previous estimates of $0.06 and $0.07. The revisions suggest analysts expect profitability to deteriorate more than previously anticipated.
• Negative Sentiment: Forecasts for 2027 were also reduced: full-year EPS moved from a $0.67 profit to a $0.50 loss, while estimates for the first three quarters were set at losses of $0.30, $0.15 and $0.05 per share. Fourth-quarter 2027 EPS was reduced to breakeven from a projected $0.36 profit.
• Negative Sentiment: The largest revisions affected the longer-term outlook. HC Wainwright cut EPS estimates from $2.49 to $0.15 for 2028, from $4.51 to $0.71 for 2029, and from $5.76 to $1.14 for 2030. These cuts materially reduce the anticipated earnings growth story and are likely the main reason the stock has been trending lower.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.